This presentation discusses the possibility of finding a cure for type 1 diabetes, and hereby developing a product, that maintains a normal blood glucose level without insulin treatment. In continuation of this, we’ll provide an introduction to beta cell replacement therapy based on The Edmonton Protocol, however we’ll be focusing on relying on stem cell technology rather than that of organ donor islets. Furthermore we’ll discuss how we can combine an encapsulation strategy, so we can avoid the use of immuno-suppression.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

In this presentation we’ll take a closer look at the relation between obesity and diabetes. Although it may seem simple, there are various aspects that make the relation between obesity and diabetes, more complex than at first sight.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

In this lecture we’ll discuss the role of inflammation in type 2 diabetes. In patients with type 2 diabetes, cardiovascular complications are of particular interest, as these are mainly responsible for the increase of mortality and obesity in diabetic patients compared with healthy subjects. In continuation of this and in order to understand why diabetes is an inflammatory disease, we’ll provide an introduction to the acute phase response.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

In this presentation we’ll translate our knowledge from genetics into clinically relevant patient stories. We’ll present case stories of translational metabolism, which means that we go from genotype to phenotype. Translational science is a multidisciplinary form of science that bridges the gap between basic science and applied science.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

In this presentation aim to increase the student’s knowledge about translational metabolism, in continuation of this we’ll elaborate on topics related to food ingestion, bone resorption, the intestinale hormone GIP, genetic variation in the receptor of GIP in relation to fracture risk, food availability and bone regulation, blood glucose and future treatment of osteoporosis.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation discuss how to treat hyperglycaemia in patients with type 2 diabetes. The cornerstone in the treatment is weight loss and increased physical activity, but most patients need pharmacological treatment from the time of diagnosis in order to control hyperglycemia. Furthermore we’ll discuss the use of all diabetic agents in patient with type 2 diabetes and how it’s important that the anti diabetic treatment is individualized.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation discuss the new antidiabetic agents. We have the incretin based therapy which include two groups of drugs, DDP-4 inhibitors and GLP-1 receptor agonist. Furthermore we’ll provide an introduction to the hormones GLP-1 and GIP and their effect on insulin.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation focuses on the treatment of hyperglycaemia with type 2 diabetes patients. We’ll provide an introduction to exenatide, liraglutide, GLP-1 receptor antagonist, combination therapy, DPP-4 inhibitor, pancreatic safety of incretin-based drugs, SGLT-2 inhibitor and glucose absorption.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation provides an introduction to Sodium-glucose linked transporter 2 inhibitors (SGLT-2) and how it affects the blood glucose. Furthermore we’ll discuss how SGLT-2 inhibitors can be used for treating patients with type 2 diabetes. Three SGLT-2 inhibitors have been approved: Dapa, Empa and Canagliflozin, for clinical use in patients with type 2 diabetes.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation focus on the question: can we cure diabetes? By interviewing different experts we will estimate how possible it is that we will find a cure for diabetes in the future. One of the main arguments is that we already have a cure, which is eating right and exercise, but the big question is whether people are willing to take this cure?

Narrator: Richard Steed.

This presentation discuss how we can fight the global diabetes epidemic. According to WHO (2016) the incidence and impacts of diabetes can largely be prevented or reduced with an approach that incorporates evidence-based, affordable, cost-effective, population-wide and multi-sector intervention. So which interventions should we prioritize as the most efficient interventions to fight the global diabetes epidemic?

Narrator: Richard Steed.

Many people exercise and take medicine in order to delay or treat type 2 diabetes. However in most cases these interventions in one’s lifestyle fails and the person regain weight and retain their increasing blood glucose levels. Controlling one’s appetite seems to be the key, which is one of the aspects we’ll discuss in this presentation. Furthermore we’ll discuss how gastric bypass surgery helps people with diabetes type 2 controlling their appetite and make their diabetes disappear. Finally we’ll discuss how hormones such as GLP-1 can help diabetics’ control their appetite, and lose weight.

Narrator: Richard Steed.

This presentation focus on which role nutrition plays in developing diabetes and how obesity affects diabetes development. Obesity and weight gain dramatically increase the risk of developing type 2 diabetes. But it’s not only the total calorie intake and the BMI that counts, so does the distribution between fat, protein and carbohydrates, in other words the composition of nutritions. In continuation of this it will be discussed how a restricting intake of carbohydrates might be the way to reduce or even eliminate the use of medication in diabetes treatments.

Narrator: Richard Steed.

This presentation address how being overweight and obese is considered one of the strongest predictors, regarding the development of type 2 diabetes. Almost 85 % of people living with diabetes type 2, are either overweight or obese. This is an important aspect, because globally we have a lot of overweight people, in fact in 2014, one in three adults was overweight and one in eight was obese. But why do the numbers keep growing and what’s causing this epidemic growth of obesity?

Narrator: Richard Steed.

This presentation provides an introduction to Diabetes.What is diabetes and what happens in the body? You will learn how diabetes is a term used to describe the body’s inability to produce sufficient amounts of insulin and how insulin as a pancreatic hormone functions as a main glucose regulator, that makes sure our glucose levels are balanced. Both high and low blood glucose levels are dangerous. When you have diabetes, the lack of insulin will cause high blood glucose levels, which affects several parts of your body.

Narrator: Richard Steed.

In this presentation you will learn about the evolution of diabetes and how it affects the world population. Diabetes is probably recognized as one of the biggest global health challenges in the 21st century. Figures from 2012 shows that diabetes caused the death of 1.5 million people and lead to an additional 2.2 million deaths caused by higher than optimal blood glucose, which increases the risk of cardiovascular and other diseases. The prevalence of diabetes is rising in all income groups, however over the past decade it has risen faster in low and middle income countries rather than in high income countries.

Narrator: Richard Steed.

This presentation talks about who is at risk of developing diabetes and how diabetes will affect the future generations. You will be introduced to how the global amount of people diagnosed with diabetes, according to the WHO and the IDF, will increase from just over 400 million to 600 million by 2030.

Narrator: Richard Steed.

In a world of 24-hour news cycles, social media, and deep fakes it is difficult to discern what is true, what is opinion, and what is out-right false. The ability and habit of fact-checking information is increasingly important in light of recent global health crises and upcoming elections. This course will cover strategies for identifying misleading media, fact-checking news, and engaging in critical discussions about the information that we consume and share. This course is designed to dicussion-based and focused on personal reflection and practice. This course was created for the Honors Program at NC State University

Scientists who are working to discover new medicines often use robots to prepare samples of cells, allowing them to test chemicals to identify those that might be used to treat diseases. Students will meet a scientist who works to identify new medicines. She created free software that ''looks'' at images of cells and determines which images show cells that have responded to the potential medicines. Students will learn about how this technology is currently enabling research to identify new antibiotics to treat tuberculosis. Students will complete hands-on activities that demonstrate how new medicines can be discovered using robots and computer software, starring the student as ''the computer.'' In the process, the students learn about experimental design, including positive and negative controls.

Word Count: 52779

(Note: This resource's metadata has been created automatically by reformatting and/or combining the information that the author initially provided as part of a bulk import process.)